Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paediatric idarucizumab emergency reversal safety trial in dabigatran-treated VTE patients
2015-002177-37Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2016
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of idarucizumab in venous thromboembolism (VTE), sponsored by Boehringer Ingelheim. Primary endpoint: Safety of idarucizumab. Started Mar 2016; status: completed.
02
Drugs
idarucizumab
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on 2015-002177-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002177-37.